POS0881 EFFICACY AND SAFETY OF SUBCUTANEOUS BRODALUMAB, A FULLY HUMAN ANTI–IL-17RA MONOCLONAL ANTIBODY, FOR SYSTEMIC SCLEROSIS WITH MODERATE-TO-SEVERE SKIN THICKENING: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 3 STUDY
Takemichi Fukasawa, Asako Yoshizaki, H. Kagebayashi, S. Sato
Topics & Concepts
MedicinePlaceboInternal medicineClinical endpointConnective tissue diseaseRandomized controlled trialDermatologyGastroenterologyPathologyAutoimmune diseaseDiseaseAlternative medicineSystemic Sclerosis and Related DiseasesAutoimmune Bullous Skin DiseasesDermatological and Skeletal Disorders